Online citations, reference lists, and bibliographies.
← Back to Search

Toward The Establishment Of Standardized In Vitro Tests For Lipid-Based Formulations. 5. Lipolysis Of Representative Formulations By Gastric Lipase

Jean-Claude Bakala-N’Goma, H. Williams, P. Sassene, Karen Kleberg, Marilyn Calderone, V. Jannin, A. Igonin, Anette Partheil, D. Marchaud, Eduardo Jule, J. Vertommen, M. Maio, Ross D. Blundell, H. Benameur, A. Müllertz, C. Pouton, C. H. Porter, F. Carrière
Published 2014 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PurposeLipid-based formulations (LBF) are substrates for digestive lipases and digestion can significantly alter their properties and potential to support drug absorption. LBFs have been widely examined for their behaviour in the presence of pancreatic enzymes. Here, the impact of gastric lipase on the digestion of representative formulations from the Lipid Formulation Classification System has been investigated.MethodsThe pHstat technique was used to measure the lipolysis by recombinant dog gastric lipase (rDGL) of eight LBFs containing either medium (MC) or long (LC) chain triglycerides and a range of surfactants, at various pH values [1.5 to 7] representative of gastric and small intestine contents under both fasting and fed conditions.ResultsAll LBFs were hydrolyzed by rDGL. The highest specific activities were measured at pH 4 with the type II and IIIA MC formulations that contained Tween®85 or Cremophor EL respectively. The maximum activity on LC formulations was recorded at pH 5 for the type IIIA-LC formulation. Direct measurement of LBF lipolysis using the pHstat, however, was limited by poor LC fatty acid ionization at low pH.ConclusionsSince gastric lipase initiates lipid digestion in the stomach, remains active in the intestine and acts on all representative LBFs, its implementation in future standardized in vitro assays may be beneficial. At this stage, however, routine use remains technically challenging.
This paper references
10.1016/j.drudis.2011.11.007
Bridging solubility between drug discovery and development.
Li Di (2012)
10.1074/jbc.274.24.16995
Crystal Structure of Human Gastric Lipase and Model of Lysosomal Acid Lipase, Two Lipolytic Enzymes of Medical Interest*
A. Roussel (1999)
10.1016/0005-2760(86)90234-1
Importance of human gastric lipase for intestinal lipolysis: an in vitro study.
Y. Gargouri (1986)
10.1124/PR.112.005660
Strategies to Address Low Drug Solubility in Discovery and Development
H. Williams (2013)
10.1016/j.ijpharm.2010.04.019
The effects of excipients on transporter mediated absorption.
J. Goole (2010)
10.1016/0016-5085(86)90695-5
Kinetic assay of human gastric lipase on short- and long-chain triacylglycerol emulsions.
Y. Gargouri (1986)
10.1016/S0968-0896(96)00251-9
In vivo and in vitro studies on the stereoselective hydrolysis of tri- and diglycerides by gastric and pancreatic lipases.
F. Carrière (1997)
10.1016/J.ADDR.2007.05.006
Oral lipid-based formulations.
D. Hauss (2007)
10.1023/A:1016268311867
Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects
P. Constantinides (2004)
10.1074/JBC.M109484200
Crystal Structure of the Open Form of Dog Gastric Lipase in Complex with a Phosphonate Inhibitor*
A. Roussel (2002)
10.1016/j.bbalip.2008.05.006
Lipolysis of the semi-solid self-emulsifying excipient Gelucire 44/14 by digestive lipases.
S. Fernandez (2008)
10.1517/17425250903176439
The effect of oral lipids and circulating lipoproteins on the metabolism of drugs
Jigar P. Patel (2009)
Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells.
T. Lindmark (1998)
10.1111/J.1432-1033.1991.TB16346.X
Purification and biochemical characterization of dog gastric lipase.
F. Carrière (1991)
10.1002/JPS.20780
Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies.
P. Constantinides (2007)
10.1016/S1542-3565(04)00601-9
Quantitative study of digestive enzyme secretion and gastrointestinal lipolysis in chronic pancreatitis.
F. Carrière (2005)
10.1152/AJPGI.2001.281.1.G16
Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers.
F. Carrière (2001)
10.1021/mp300331z
Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
H. Williams (2012)
10.4155/TDE.11.138
Understanding the lipid-digestion processes in the GI tract before designing lipid-based drug-delivery systems.
J. Bakala N'Goma (2012)
10.2174/138161209788682479
Drug-like property concepts in pharmaceutical design.
Li Di (2009)
10.1177/00970002042006005
A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals
M. Martinez (2002)
10.1016/0014-5793(78)80244-0
Ionization of fatty acids at the lipid—water interface
M. Egret‐Charlier (1978)
10.3109/00365529309098247
Gastric and pancreatic lipase levels during a test meal in dogs.
F. Carrière (1993)
10.1007/S13228-011-0014-5
In Vitro Gastrointestinal Lipolysis: Replacement of Human Digestive Lipases by a Combination of Rabbit Gastric and Porcine Pancreatic Extracts
P. Capolino (2011)
10.1007/s11095-013-1038-z
Toward the Establishment of Standardized In Vitro Tests for Lipid-Based Formulations, Part 3: Understanding Supersaturation Versus Precipitation Potential During the In Vitro Digestion of Type I, II, IIIA, IIIB and IV Lipid-Based Formulations
H. Williams (2013)
10.1016/S0928-0987(00)00167-6
Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems.
C. Pouton (2000)
10.1016/J.ADDR.2007.10.014
Enhancing intestinal drug solubilisation using lipid-based delivery systems.
C. H. Porter (2008)
In vivo and in vitro studies on the stereoselective hydrolysis of tri- and 1286 Bakala-N’Goma et al. diglycerides by gastric and pancreatic lipases
F Carriere (1997)
10.1053/GAST.2000.18140
The specific activities of human digestive lipases measured from the in vivo and in vitro lipolysis of test meals.
F. Carrière (2000)
10.1039/c4fo00045e
In vitro digestion of citric acid esters of mono- and diglycerides (CITREM) and CITREM-containing infant formula/emulsions.
S. Amara (2014)
10.1002/HEP.1840040814
The Ionization Behavior of Fatty Acids and Bile Acids in Micelles and Membranes
D. Small (1984)
10.1016/0005-2760(68)90069-6
Action of some effectors on the hydrolysis of long-chain triglycerides by pancreatic lipase.
G. Benzonana (1968)
10.1016/0005-2744(68)90168-X
Sur le role des ions calcium durant l'hydrolyse des triglycerides insolubles par la lipase pancreatique en presence de sels biliares
G. Benzonana (1968)
10.1038/nrd2197
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
C. H. Porter (2007)
10.1007/s11095-009-9906-2
In Vitro Gastrointestinal Lipolysis of Four Formulations of Piroxicam and Cinnarizine with the Self Emulsifying Excipients Labrasol® and Gelucire® 44/14
S. Fernandez (2009)
10.1124/dmd.105.008102
AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT
Natalie L Trevaskis (2006)
10.1007/s11095-013-1053-0
In Vitro Digestion of the Self-Emulsifying Lipid Excipient Labrasol® by Gastrointestinal Lipases and Influence of its Colloidal Structure on Lipolysis Rate
S. Fernandez (2013)
10.1002/3527601910.CH10
Physiology of Gastrointestinal Lipolysis and Therapeutical Use of Lipases and Digestive Lipase Inhibitors
H. Lengsfeld (2005)
10.1002/jps.23205
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations.
H. Williams (2012)
10.3109/10425179809008461
The complete cDNA sequence encoding dog gastric lipase.
S. Vaganay (1998)
10.1016/0016-5085(93)90908-U
Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans.
F. Carrière (1993)
10.1016/J.ADDR.2007.10.009
Lipid-based systems for the enhanced delivery of poorly water soluble drugs.
C. H. Porter (2008)
10.1016/J.BBALIP.2007.02.009
Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol, medium chain glycerides and PEG esters.
S. Fernandez (2007)
10.1039/c2fo10248j
Coupling in vitro gastrointestinal lipolysis and Caco-2 cell cultures for testing the absorption of different food emulsions.
C. Vors (2012)
10.1016/0005-2760(91)90136-6
Inactivation of pancreatic and gastric lipases by THL and C12:0-TNB: a kinetic study with emulsified tributyrin.
Y. Gargouri (1991)



This paper is referenced by
10.1007/s11095-020-2762-9
Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations
Yusuke Tanaka (2020)
years of oral lipid-based formulations : Provenance , progress and future perspectives ☆
O. Feeney (2016)
10.1016/J.FOODHYD.2019.105218
Impact of different oil gelators and oleogelation mechanisms on digestive lipolysis of canola oil oleogels
Areen Ashkar (2019)
10.1186/s12944-018-0757-x
Biopharmaceutical insights of particulate emulsified systems - a prospective overview
Jyothshna Devi Katamreddy (2018)
10.1021/acs.molpharmaceut.7b00660
Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
Claire L McEvoy (2017)
10.1208/s12249-017-0785-2
Self-emulsification of Lipidic Drug Delivery System in Pure Water and in Concentrated Glycerol Solution
C. Planchette (2017)
Bio-relevant characterisation of lipidic formulations and prediction of in vivo exposure
Paloma Benito-Gallo (2017)
Improved Molecular Understanding of Lipid-Based Formulations : for Enabling Oral Delivery of Poorly Water-Soluble Drugs
Linda C Alskär (2018)
10.1016/j.addr.2016.04.007
50years of oral lipid-based formulations: Provenance, progress and future perspectives.
O. Feeney (2016)
10.1016/j.addr.2016.04.001
Lipid-based nanocarriers for oral peptide delivery.
Zhigao Niu (2016)
10.1016/j.addr.2018.11.003
Drug supersaturation during formulation digestion, including real-time analytical approaches.
M. Kuentz (2018)
10.1021/ACS.MOLPHARMACEUT.6B00413
In Vivo Precipitation of Poorly Soluble Drugs from Lipid-Based Drug Delivery Systems.
P. Sassene (2016)
10.1039/C6FO00158K
Comparison of lipases for in vitro models of gastric digestion: lipolysis using two infant formulas as model substrates.
P. Sassene (2016)
10.1007/s11095-015-1843-7
A new in vitro lipid digestion – in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations
Matthew F. Crum (2015)
10.1016/j.ejpb.2015.04.027
Chain length affects pancreatic lipase activity and the extent and pH-time profile of triglyceride lipolysis.
Paloma Benito-Gallo (2015)
10.1007/s11095-017-2327-8
Caco-2 Cell Conditions Enabling Studies of Drug Absorption from Digestible Lipid-Based Formulations
Janneke Keemink (2017)
10.1016/J.FOODHYD.2014.11.020
Influence of emulsifier type on gastrointestinal fate of oil-in-water emulsions containing anionic dietary fiber (pectin)
Ruojie Zhang (2015)
10.1016/j.jconrel.2017.03.393
In vitro and in vivo performance of monoacyl phospholipid‐based self‐emulsifying drug delivery systems
T. Tran (2017)
10.1016/j.addr.2019.03.005
Variations in gastrointestinal lipases, pH and bile acid levels with food intake, age and diseases: Possible impact on oral lipid-based drug delivery systems.
S. Amara (2019)
10.1002/mnfr.201500883
Infant digestion physiology and the relevance of in vitro biochemical models to test infant formula lipid digestion.
L. Poquet (2016)
10.1080/10408398.2014.970267
Standardization of Nanoparticle Characterization: Methods for Testing Properties, Stability, and Functionality of Edible Nanoparticles
Jake McClements (2016)
10.1016/j.biochi.2015.11.016
Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs.
F. Carrière (2016)
10.1016/j.addr.2019.06.010
In vitro digestion models to evaluate lipid based drug delivery systems; present status and current trends.
R. Berthelsen (2019)
10.1007/s11095-017-2289-x
Lipids in the Stomach – Implications for the Evaluation of Food Effects on Oral Drug Absorption
M. Koziolek (2017)
10.1039/c5fo00930h
Relevant pH and lipase for in vitro models of gastric digestion.
L. Sams (2016)
10.1016/j.ijpharm.2017.12.032
Size characterization of lipid-based self-emulsifying pharmaceutical excipients during lipolysis using Taylor dispersion analysis with fluorescence detection.
J. Chamieh (2018)
10.26180/5DEA0300E177B
Oral lipid-based drug delivery: Inhibiting and eliminating digestion to improve absorption of poorly soluble drugs.
O. Feeney (2019)
10.1016/j.ejps.2016.08.060
The dynamic gastric environment and its impact on drug and formulation behaviour.
J. Van Den Abeele (2017)
10.3390/ijms20030669
Lipomatrix: A Novel Ascorbyl Palmitate-Based Lipid Matrix to Enhancing Enteric Absorption of Serenoa Repens Oil
A. Fratter (2019)
10.1039/c9fo01867k
In vitro digestion of galactolipids from chloroplast-rich fraction (CRF) of postharvest, pea vine field residue (haulm) and spinach leaves.
Jutarat Wattanakul (2019)
10.1016/j.ejmech.2016.08.009
Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis.
V. Point (2016)
10.1016/j.ijpharm.2016.04.044
Impact of lipases on the protective effect of SEDDS for incorporated peptide drugs towards intestinal peptidases.
G. Leonavičiūtė (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar